Dr Herbert Ho Fung Loong speaks to ecancer about a randomised phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC.


Selpercatinib is a highly selective and potent, brain penetrant RET inhibitor, approved for the treatment of advanced RET fusion-positive (RET+) NSCLC. The study investigated the use of first-line selpercatinib for the treatment of RET fusion-positive NSCLC.


The results demonstrated superior progression-free survival with a targeted therapy compared to chemotherapy and pembrolizumab. Dr Loong notes that these results support comprehensive genomic testing at diagnosis and treatment with first-line selpercatinib in patients with advanced RET+ NSCLC.